Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMUS: Olaptesed pegol + pembrolizumab in metastatic pancreatic cancer
NCT04901741Phase 2Not yet recruiting
- Sponsor
- TME Pharma
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, Small Molecules
01
Overview
Phase 2, open-label trial of olaptesed pegol (2 arms), sponsored by TME Pharma. Primary endpoint: Disease Control Rate at 6 weeks. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
olaptesed pegol
Beyond the preview
Go deeper on NCT04901741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04901741.